Chiara Fenoglio

List of Publications by Year
in descending order

59 papers	3,356 citations	159525 30 h-index	155592 55 g-index
60 all docs	60 docs citations	60 times ranked	6722 citing authors

#	Article	IF	Citations
1	Circular RNAs: Emblematic Players of Neurogenesis and Neurodegeneration. International Journal of Molecular Sciences, 2022, 23, 4134.	1.8	19
2	Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools. Cells, 2021, 10, 1733.	1.8	18
3	Role of Oxidative Damage in Alzheimerâ€™s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery. Antioxidants, 2021, 10, 1353.	2.2	57
4	Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimerâ€™s Disease. Pharmaceuticals, 2021, 14, 1187.	1.7	17
5	C9ORF72 hexanucleotide repeat expansion frequency in patients with Paget's disease of bone. Neurobiology of Aging, 2020, 85, 154.e1-154.e3.	1.5	4
6	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimerâ€™s Disease. Cells, 2020, 9, 1443.	1.8	60
7	IL-33 and its decoy sST2 in patients with Alzheimerâ€™s disease and mild cognitive impairment. Journal of Neuroinflammation, 2020, 17, 174.	3.1	36
8	Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2019, 11, 232.	1.7	112
9	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. Journal of Alzheimer's Disease, 2019, 67, 1173-1179.	1.2	4
10	Lag-time in Alzheimerâ€™s disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform. Immunity and Ageing, 2019, 16, 7.	1.8	15
11	Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy. Journal of Cellular and Molecular Medicine, 2018, 22, 2670-2679.	1.6	8
12	Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2018, 61, 1289-1294.	1.2	2
13	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimerâ€™s Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 62, 913-932.	1.2	54
14	CSF Î²-amyloid and white matter damage: a new perspective on Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 352-357.	0.9	36
15	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
16	Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 314-321.	2.5	26
17	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
18	Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementia. Expert Review of Neurotherapeutics, 2018, 18, 469-475.	1.4	6

#	Article	IF	Citations
19	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
20	Progranulin as a therapeutic target for dementia. Expert Opinion on Therapeutic Targets, 2018, 22, 579-585.	1.5	17
21	Recognition of viral and self-antigens by T H 1 and T H 1/T H 17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. Journal of Allergy and Clinical Immunology, 2017, 140, 797-808.	1.5	59
22	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Scientific Reports, 2017, 7, 43718.	1.6	35
23	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
24	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
25	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
26	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. Journal of Alzheimer's Disease, 2017, 61, 47-52.	1.2	8
27	CSF Î²-amyloid as a putative biomarker of disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1085-1091.	1.4	33
28	Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. Movement Disorders, 2017, 32, 476-478.	2.2	6
29	PRNP P39L Variant is a Rare Cause ofÂFrontotemporal Dementia in Italian Population. Journal of Alzheimer's Disease, 2016, 50, 353-357.	1.2	15
30	Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. Journal of Alzheimer's Disease, 2016, 53, 445-449.	1.2	3
31	Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 59-65.	1.2	41
32	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2016, 52, 1203-1208.	1.2	18
33	Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 81-83.	1.1	39
34	Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation. Journal of Alzheimer's Disease, 2016, 54, 717-721.	1.2	7
35	Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1007-1012.	1.4	12
36	Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. Journal of the Neurological Sciences, 2016, 362, 283-286.	0.3	22

#	Article	IF	Citations
37	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica, 2016, 131, 925-933.	3.9	262
38	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 771-776.	1.2	14
39	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	4.4	121
40	Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations. International Journal of Molecular Sciences, 2015, 16, 1385-1394.	1.8	14
41	The Novel GRN g.1159_1160delTG Mutation is Associated with Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2015, 44, 277-282.	1.2	7
42	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. PLoS ONE, 2015, 10, e0140639.	1.1	4
43	Incomplete Penetrance of the C9ORF72 Hexanucleotide Repeat Expansions: Frequency in a Cohort of Geriatric Non-Demented Subjects. Journal of Alzheimer's Disease, 2014, 39, 19-22.	1.2	27
44	Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1261-1267.	1.2	188
45	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	1.5	134
46	Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations andÂ C9orf72 repeat expansions. Neurobiology of Aging, 2014, 35, 2658.e1-2658.e5.	1.5	33
47	The C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiology of Aging, 2014, 35, 1214.e7-1214.e10.	1.5	49
48	C9ORF72 repeat expansion not detected in patients with multiple sclerosis. Neurobiology of Aging, 2014, 35, 1213.e1-1213.e2.	1.5	6
49	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 49-52.	1.1	2
50	Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. Journal of Affective Disorders, 2014, 166, 330-333.	2.0	85
51	Phenotypic Variability associated with the C9ORF72 Hexanucleotide Repeat Expansion: A Sporadic Case of Frontotemporal Lobar Degeneration with Prodromal Hyposmia and Predominant Semantic Deficits. Journal of Alzheimer's Disease, 2014, 40, 849-855.	1.2	5
52	Transmembrane Protein 106B Gene (TMEM106B) Variability and Influence on Progranulin Plasma Levels in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 757-761.	1.2	2
53	Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurological Sciences, 2013, 34, 899-903.	0.9	30
54	Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1938-1942.	1.4	98

#	Article	IF	Citations
55	An Emerging Role for Long Non-Coding RNA Dysregulation in Neurological Disorders. International Journal of Molecular Sciences, 2013, 14, 20427-20442.	1.8	62
56	Optimal Plasma Progranulin Cutoff Value for Predicting Null Progranulin Mutations in Neurodegenerative Diseases: A Multicenter Italian Study. Neurodegenerative Diseases, 2012, 9, 121-127.	0.8	88
57	MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis. International Journal of Molecular Sciences, 2012, 13, 13227-13239.	1.8	61
58	Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. Journal of Alzheimer's Disease, 2011, 24, 253-259.	1.2	62
59	Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. Journal of the Neurological Sciences, 2009, 287, 291-293.	0.3	83